#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Management of children with infantile hemangioma treated by systemic propranolol


Authors: J. Mališ 1;  A. Mišove 1;  S. Zimová 1;  K. Bláhová 2;  V. Stará 2;  N. Krejčová 2;  M. Kynčl 3;  M. Dvořáková 3;  B. Prosová 3;  M. Šimsová 4;  R. Katra 5;  A. Sukop 6
Authors‘ workplace: Klinika dětské hematologie a onkologie 2. LF UK a FN Motol, Praha 1;  Pediatrická klinika 2. LF UK a FN Motol, Praha 2;  Klinika zobrazovacích metod 2. LF UK a FN Motol, Praha 3;  Klinika dětské chirurgie 2. LF UK a FN Motol, Praha 4;  Klinika ušní, nosní a krční 2. LF UK a FN Motol, Praha 5;  Klinika plastické chirurgie 3. LF UK a FN Královské Vinohrady, Praha 6
Published in: Čes-slov Pediat 2020; 75 (5): 285-291.
Category: Review

Overview

Infantile hemangioma (IH) occurs in 5 to 10% of children under one year of age. This benign vascular tumor is characterized by three phases of growth – proliferation, plateau and involution. Modern non-selective 
β-blocker systemic therapy (propranolol) offers children an effective, safe and non-invasive solution. Starting the therapy in the proliferative phase is crucial for effectiveness.

Keywords:

infantile hemangioma – propranolol


Sources

1. Kilcline C. Infantile hemangiomas: How common are they? A systematic review of the medical literature. Pediatr Dermatol 2008; 25 (2): 168–173.

2. Léauté-Labrèze C. Infantile haemangioma: Part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities. J Eur Acad Dermatol Venereol 2011; 25 (11): 1245–1253.

3. Baselga E. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatol 2016; 152 (11): 1239–1243.

4. Léauté-Labrèze C. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 372 (8): 735–746.

5. Mališ J, Faberová R, Bučková H, et al. Současné terapeutické možnosti u infantilních hemangiomů. Čes-slov Dermatol 2017; 92 (2): 103–108. ISSN: 0009-0514.

6. Léauté-Labrèze C, Baselga Torres E, et al. The infantile hemangioma referral score: A validated tool for physicians. Pediatrics 2020 Apr; 145 (4): e20191628. doi: 10.1542/peds.2019-1628.

7. Léauté-Labrèze C. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358 (24): 2649–2651.

8. Vredenborg AD. Multiple cutaneous infantile haemangiomas and the risk of internal haemangioma. Br J Dermatol 2013; 169 (1): 188–191.

9. Chang L, Lv D, Yu Z, et al. Infantile hemangioma: factors causing recurrence after propranolol treatment. Pediatr Res 2018; 83: 175–182.

10. Bagazgoitia L, Hernandez-Martin A, Torrelo A. Recurrence of infantile hemangiomas treated with propranolol. Pediatr Dermatol 2011; 28: 658–662.

11. Mališ J, Stará V, Bláhová K, et al. Infantilní hemangiomy. Současné léčebné postupy. Čes-slov Pediat 2017; 72 (4): 245–254. ISSN: 0069-2328; 1805-4501

Labels
Neonatology Paediatrics General practitioner for children and adolescents
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#